Avidity Biosciences, Inc.’s bullish RNA thesis was summarized by AnotherBio. Novartis is acquiring Avidity RNA in a straightforward deal expected to close in the first half of 2026, with a small SpinCo component holding cash and collaboration rights. This SpinCo could be sold back to collaborators, potentially eliminating it entirely. Cash provides a valuation floor, and the deal presents a low-risk opportunity with potential upside.

A separate article highlighted Capricor Therapeutics, Inc.’s bullish thesis on Deramiocel’s pending FDA decision, leading to stock depreciation. Avidity Biosciences, Inc. is not among the 30 Most Popular Stocks Among Hedge Funds, with 26 hedge funds holding RNA at the end of the second quarter. While RNA presents investment potential, some AI stocks offer greater upside and less downside risk, particularly those benefiting from Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: Avidity Biosciences, Inc. (RNA): A Bull Case Theory